SM
LXRX icon

Sabby Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Sabby Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,563
Closed -$2.24M – 241
2017
Q1 		$2.24M Hold
1,563
– – 0.12% 83
2016
Q4 		$2.16M Sell
1,563
-4,700
-75% -$75.4K 0.13% 97
2016
Q3 		$11.3M Buy
6,263
+943
+18% +$15.2K 0.42% 41
2016
Q2 		$7.63M Buy
5,320
+1,228
+30% +$16.7K 0.4% 43
2016
Q1 		$4.89M Buy
4,092
+1,357
+50% +$14.2K 0.24% 44
2015
Q4 		$3.64M Buy
2,735
+2,225
+436% +$27.4K 0.2% 78
2015
Q3 		$548K Buy
+510
New +$5.57K 0.02% 285

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sabby Management's LXRX Position: Q2 2017 in Review

Sabby Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2017, closing a stake of 28,626 shares — an estimated $443K sold.

Sabby Management first reported a position in LXRX in Q4 2013 and held it in 8 quarters. The position peaked at $5.07M in Q1 2015. 136 funds tracked by Wall St. Rank hold LXRX as of Q2 2017.

  • Sabby Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Sabby Management sold 28,626 Lexicon Pharmaceuticals shares in Q2 2017, an estimated $443K.
  • Sabby Management first reported a position in Lexicon Pharmaceuticals in Q4 2013 and held it in 8 quarters.
  • Sabby Management's Lexicon Pharmaceuticals position peaked at $5.07M in Q1 2015.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.